Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)		Docket Number (Optional) ST99019 US PCT	
ADMIDDIED DISSELLISIONALLS DISPLICATIONS	. 101(0)	1	
First named inventor: Michel PERRICAUDET et al.			
Application No.: 10/018,273	Art Unit:	1648	
Filed: August 07, 2002	Examiner:	BOESEN, Agnieszka	
Title: RECOMBINANT ADENOVIRUSES ENCODING THE SPECIFIC IODINE TRANSPORTER (NIS)			
Attention: Office of Petitions Mail Stop Petition Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 FAX (571) 273-8300 NOTE: If information or assistance is needed in completing this form, please contact Petitions			
Information at (571) 272-3282.			
The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the office notice or action plus an extensions of time actually obtained.			
APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION			
NOTE: A grantable petition requires the following items: (1) Petition fee; (2) Reply and/or issue fee; (3) Terminal disclaimer with disclaimer fee - required for all utility and plant applications filed before June 8, 1995; and for all design applications; and (4) Statement that the entire delay was unintentional.			
1.Petition fee S (37 CFR 1.17(m)). Applicant claims small entity status. See 37 CFR 1.27. V Other than small entity – fee \$ 1,500.00 (37 CFR 1.17(m))			
Reply and/or fee A. The reply and/or fee to the above-noted Office action the form of _a continuation application filed concurrently	(is		
has been filed previously onis enclosed herewith.			
B. The issue fee and publication fee (if applicable) of \$has been paid previously onis enclosed herewith.			

[Page 1 of 2]
This collection of information is required by 37 CFR 1.137(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/S8/84 (19-05)
Approved for use through 07/31/2906, OM8 9651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Terminal disclaimer with disclaimer fee			
Since this utility/plant application was filed on	or after June 8, 1995, no terminal disclaimer is required.		
A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ for a small entity or \$ for other than a small entity) disclaiming the required period of time is enclosed herewith (see			
PTO/SB/63). 4. STATEMENT: The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional. [NOTE: The United States Patent and Trademark Office may require additional information if there is a question as to whether either the abandonment or the delay in filing a petition under 37 CFR 1.137(b) was unintentional (MPEP 711.03(c), subsections (III)(C) and (D)).] WARNING:			
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may			
contribute to identity theft. Personal information such a numbers (other than a check or credit card authorization to the USPTO to support a petition or an application. If this ty USPTO, petitioners/applicants should consider redacting sit to the USPTO. Petitioner/applicant is advised that the recoff the application (unless a non-publication request in compose a patent. Furthermore, the record from an abandoned	s social security numbers, bank account numbers, or credit card rm PTO-2038 submitted for payment purposes) is never required by pe of personal information is included in documents submitted to the uch personal information from the documents before submitting them ord of a patent application is available to the public after publication pliance with 37 CFR 1.213(a) is made in the application) or issuance application may also be available to the public if the application is see 37 CFR 1.14). Checks and credit card authorization forms PTO-		
	September 25, 2009		
Signature	Date		
Ann Marie Szczepanik	52,267		
Typed or printed name	Registration Number, if applicable		
Sanofi-Aventis Inc.	908 231-4757		
Address	Telephone Number		
Route 202-206, P.O. Box 680	·		
Address			
Mail Code D-303A, Bridgewater, N.	08807		
Address			
Enclosures: Fee Payment			
Reply			
Terminal Disclaimer Form			
Additional sheets containing statements establishing unintentional delay			
Other:			
Economic Control Contr			
I hereby certify that this correspondence is bein Deposited with the United States Pos postage as first class mail in an enve Patents, P. O. Box 1450, Alexandria,	tal Service on the date shown below with sufficient lope addressed to: Mail Stop Petition, Commissioner for		
500	-		
	Typed or printed name of person signing certificate		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Examiner: BOESEN, Agnieszka

PERRICAUDET, et al.

Art Unit: 1648

Application No.: 10/018,273

Filed: August 7, 2002

Title: RECOMBINANT ADENOVIRUSES

ENCODING THE SPECIFIC IODINE

TRANSPORTER (NIS)

PETITION FOR REVIVAL OF AN APPLICATION ABANDONED UNINTENTIONALLY

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Sir:

The above-identified application was unintentionally allowed to lapse. Applicant hereby petitions for revival of the application by submitting the petition fee, required extension of time fees, a statement that the entire delay was unintentional and a reply to the outstanding Advisory Action issued on March 11, 2009 in the form of a continuation application filed concurrently with this paper as provided under 37 CFR §1.137(c).

No additional fees are believed to be necessitated by the instant response. However, should this be in error, authorization is hereby given to charge Deposit Account no. 18-1982 for any underpayment, or to credit any overpayments.

Respectfully submitted,
/Ann Marie Szczepanik/
Ann Marie Szczepanik, Reg. No. 52,267

sanofi aventis U.S. Inc.
Patent Department
Ronte #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4757
Telefax (908) 231-2626
sanofi aventis Docket No. USSTS

sanofi aventis Docket No. USST99019 US PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Application of PERRICAUDET, et al.

Examiner:

BOESEN, Agnieszka

a arakka Cra Craya y ee sei.

Art Unit:

1648

Application No.: 10/018,273

Filed:

August 7, 2002

Title:

RECOMBINANT ADENOVIRUSES ENCODING THE SPECIFIC IODINE

TRANSPORTER (NIS)

STATEMENT REQUIRED UNDER 37 CFR §1.137

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Sir:

The above-identified application was unintentionally allowed to lapse. The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR §1.137(b) was unintentional.

Respectfully submitted,
/Ann Marie Szczepanik/
Ann Marie Szczepanik, Reg. No. 52,267

sanofi aventis U.S. Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4757
Telefax (908) 231-2626

sanofi aventis Docket No. USST99019 US PCT